research use only
Cat.No.S8702
| Related Targets | PRMT MAT2A DNA Methyltransferase LSD1 JMJD G9a/GLP MLL NSD FTO SETD |
|---|---|
| Other EZH2 Inhibitors | PF-06821497 GSK126 Tulmimetostat (CPI-0209) Valemetostat (DS-3201) GSK343 Lirametostat (CPI-1205) SHR2554 EZH2/HSP90-IN-29 |
|
In vitro |
Ethanol : 13 mg/mL
DMSO
: 3 mg/mL
(5.2 mM)
Warmed with 50°C water bath;
Ultrasonicated;
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 576.77 | Formula | C34H48N4O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2098546-05-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCC1=C(C2=C(C=C1N(CC)C3CCOCC3)OC(=C2)C4CCN(CC4)C(C)C)C(=O)NCC5=C(C=C(NC5=O)C)C | ||
| Targets/IC50/Ki |
EZH2(A667G)
(Cell-free assay) 4 nM
|
|---|---|
| In vivo |
In in vivo experiments, rats are administrated with dosages of 5 mg/kg EBI-2511 (p.o.) and 0.5 mg/kg this compound (i.v.). Mice are administrated with dosages of 10 mg/kg p.o. and 1.0 mg/kg i.v. For i.v. administration, the clearance of this compound is modest with CLz/F of 26 and 32 mL/min/kg in rats and mice, respectively. After a single 5 and 10 mg/kg oral dose of a CMC-Na suspension of this chemical to rats and mice, its AUC0‑t reaches 239 and 774 ng/mL·h with oral bioavailability of 9% and 16%, respectively. plasma protein binding of this compound in human, rat, and mouse are 93.9%, 94.0%, and 92.7%, respectively. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.